Videos

Othman Al-Sawaf, MD, provides insight into the best use of minimal residual disease in the management of patients with CLL, which he presented at the 2022 Lymphoma, Leukemia & Myeloma Congress.

Asher Chanan-Khan, MD, argues in favor of BTK inhibitors over BCL-2 inhibitors for the frontline treatment of patients with CLL in a debate at the 2022 Lymphoma, Leukemia & Myeloma Congress.

Komal Jhaveri, MD, provides insights and information regarding new and emerging antibody drug conjugate therapies for patients with triple-negative breast cancer, a topic she presented at the 2022 Great Debates & Updates in Women’s Oncology...

Jan Burger, MD, discusses relevant genetic mutations in CLL which may influence treatment decisions and reviews safety and efficacy data on new and emerging targeted agents for these patients, focusing on BTK inhibitors.

David Cescon, MD, PhD, discusses the similarities and differences in CDK4/6 inhibitors for patients with breast cancer, a topic he presented at the 2022 GDU Women’s Oncology virtual meeting.

Alvaro Arjona-Sanchez, MD, explains findings from a phase 3 studyshowing HIPEC combined with mitomycin C, administered prior to surgical resection for locally advanced colon cancer, led to an improvement in locoregional control rate.

Melissa Johnson, MD, discusses an OS update from the POSEIDON trial after a median follow-up of approximately 4 years, showing a durable long-term OS benefit by adding tremelimumab to durvalumab and chemotherapy for patients with metastatic...

Michel Ducreux, MD, reports results from a phase 3 trial showing FOLFIRINOX chemotherapy yields a significantly longer PFS vs gemcitabine for patients with locally advanced, unresectable pancreatic cancer.

Ana Aparicio, MD, discusses aggressive variants of metastatic castration-resistant prostate cancer, with a focus on treatment approaches for patients with androgen-indifferent disease.

Stéphane Oudard, MD, reports results from a phase 3 trial demonstrating that an adapted schedule of cabazitaxel reduces neutropenic complications seen in elderly patients with metastatic castration-resistant prostate cancer without...